Corvus Pharmaceuticals Income Statement (2015-2026) | CRVS

Income Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Cost of Revenue (Quarter)
0.95M1.92M
Operating items
Research & Development (Quarter)
9.11M6.99M4.79M5.10M4.92M10.37M4.08M4.59M3.97M3.96M4.00M4.08M4.11M5.22M5.97M7.45M7.87M8.45M9.94M11.18M
Selling, General & Administrative (Quarter)
2.18M2.06M2.02M2.31M2.09M2.11M1.59M1.98M1.65M1.59M1.65M2.18M1.82M2.03M2.13M2.47M2.39M2.12M2.28M3.70M
Restructuring Costs (Quarter)
0.99M0.55M0.78M0.78M0.95M0.85M0.62M0.56M1.24M
Other Operating Expenses (Quarter)
-0.99M-0.55M-0.78M-0.78M-0.95M-0.85M-0.62M-0.56M-1.24M
Operating Expenses (Quarter)
11.29M9.05M6.81M7.41M7.01M12.47M5.67M6.57M5.62M5.56M5.65M6.25M5.93M7.25M8.11M9.92M10.26M10.57M12.22M14.88M
Operating Income (Quarter)
-11.29M-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.57M-5.62M-5.56M-5.65M-6.25M-5.93M-7.25M-8.11M-9.92M-10.26M-10.57M-12.22M-14.88M
EBIT (Quarter)
-11.29M-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.57M-5.62M-5.56M-5.65M-6.25M-5.93M-7.25M-8.11M-9.92M-10.26M-10.57M-12.22M-14.88M
Non-operating items
Interest & Investment Income (Quarter)
0.32M0.43M0.57M0.51M0.53M0.64M0.74M0.60M1.78M
Non Operating Income (Quarter)
25.11M1.19M
Net income details
EBT (Quarter)
-11.29M-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.14M-5.22M-5.13M-5.25M-5.94M-3.69M-39.53M-9.94M15.73M-7.61M-9.83M-11.61M-13.09M
Profit After Tax (Quarter)
-11.75M-10.67M-9.20M-8.30M-8.36M-14.83M-9.81M-7.87M-6.50M-6.00M-6.65M-5.70M-4.26M-40.22M-12.11M15.19M-8.00M-10.16M-12.32M-13.69M
Equity Income (Quarter)
-0.46M-1.71M-2.56M-1.04M-1.60M-2.73M-4.64M-1.73M-1.28M-0.86M-1.40M0.24M-0.58M-0.68M-2.17M-0.54M-0.39M-0.32M-0.71M-0.60M
Income from Continuing Operations (Quarter)
-11.29M-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.14M-5.22M-5.13M-5.25M-5.94M-3.69M-39.53M-9.94M15.73M-7.61M-9.83M-11.61M-13.09M
Consolidated Net Income (Quarter)
-11.29M-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.14M-5.22M-5.13M-5.25M-5.94M-3.69M-39.53M-9.94M15.73M-7.61M-9.83M-11.61M-13.09M
Income towards Parent Company (Quarter)
-11.29M-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.14M-5.22M-5.13M-5.25M-5.94M-3.69M-39.53M-9.94M15.73M-7.61M-9.83M-11.61M-13.09M
Net Income towards Common Stockholders (Quarter)
-11.29M-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.14M-5.22M-5.13M-5.25M-5.94M-3.69M-39.53M-9.94M15.73M-7.61M-9.83M-11.61M-13.09M
Additional items
EPS (Basic) (Quarter)
-0.28-0.24-0.20-0.18-0.18-0.32-0.21-0.17-0.14-0.12-0.13-0.12-0.07-0.60-0.160.21-0.10-0.12-0.15-0.15
EPS (Weighted Average and Diluted) (Quarter)
-0.28-0.24-0.20-0.18-0.18-0.32-0.21-0.17-0.14-0.12-0.13-0.12-0.07-0.60-0.16-0.13-0.10-0.12-0.15-0.15
Shares Outstanding (Weighted Average) (Quarter)
38.40M43.95M41.85M46.55M46.55M46.55M46.55M46.56M47.03M48.97M48.03M49.04M54.37M58.51M60.99M72.13M77.77M77.62M78.96M90.00M
Shares Outstanding (Diluted Average) (Quarter)
38.40M43.95M41.85M46.55M46.55M46.55M46.55M46.56M47.03M48.97M48.03M49.04M60.99M75.15M
EBITDA (Quarter)
-10.37M-10.69M-8.74M-8.18M-10.01M-16.36M-9.19M-7.74M-7.44M-6.08M-6.18M-6.01M-4.34M-39.60M-12.66M15.23M-7.89M-10.07M-12.16M-13.92M